An anti-epidermal growth aspect receptor monoclonal antibody drug conjugate.

Afterwards stage clinical trials are being planned to continue to investigate ABT-414 in patients with glioblastoma multiforme.. AbbVie releases preliminary outcomes from ABT-414 Stage I study in patients with recurrent or unresectable GBM AbbVie released preliminary results from a continuing Phase I research with ABT-414, an anti-epidermal growth aspect receptor monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including a single complete response, in sufferers with unresectable or recurrent glioblastoma multiforme. Specifically, one patient experienced a comprehensive response and three sufferers experienced partial responses as measured with the Revised Evaluation in Neuro-Oncology criteria. Glioblastoma multiforme may be the most common & most aggressive type of malignant primary human brain tumor, and sufferers have few treatment options and a five-season survival rate of less than 3 %, stated Gary Gordon, M.D.‘Our objective is to make health care cheaper, easier and more readily available without dropping quality of care, ‘ stated AliveCor CEO and President Judy Wade. ‘Our aspirations are significant; we're out to make a real difference.’ AliveCor's Heart Monitor is designed for pre-sale to doctors in the U.S., beginning today, through the company website, The price is $199. AliveCor plans to begin selling the Heart Monitor in Europe in early 2013.

ADA Education Recognition system recertifies Diabetes Resource Center at Sinai Hospital The Diabetes Resource Middle at Sinai Medical center of Baltimore has been awarded recertification by the American Diabetes Association Education Recognition program.